Unknown

Dataset Information

0

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.


ABSTRACT: Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting (RR) multiple sclerosis (MS). Using the animal model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), we examined how laquinimod promotes immune modulation. Oral laquinimod treatment reversed established RR-EAE and was associated with reduced central nervous system (CNS) inflammation, decreased Th1 and Th17 responses, and an increase in regulatory T cells (Treg). In vivo laquinimod treatment inhibited donor myelin-specific T cells from transferring EAE to naive recipient mice. In vivo laquinimod treatment altered subpopulations of myeloid antigen presenting cells (APC) that included a decrease in CD11c(+)CD11b(+)CD4(+) dendritic cells (DC) and an elevation of CD11b(hi)Gr1(hi) monocytes. CD11b(+) cells from these mice exhibited an anti-inflammatory type II phenotype characterized by reduced STAT1 phosphorylation, decreased production of IL-6, IL-12/23 and TNF, and increased IL-10. In adoptive transfer, donor type II monocytes from laquinimod-treated mice suppressed clinical and histologic disease in recipients with established EAE. As effects were observed in both APC and T cell compartments, we examined whether T cell immune modulation occurred as a direct effect of laquinimod on T cells, or as a consequence of altered APC function. Inhibition of Th1 and Th17 differentiation was observed only when type II monocytes or DC from laquinimod-treated mice were used as APC, regardless of whether myelin-specific T cells were obtained from laquinimod-treated or untreated mice. Thus, laquinimod modulates adaptive T cell immune responses via its effects on cells of the innate immune system, and may not influence T cells directly.

SUBMITTER: Schulze-Topphoff U 

PROVIDER: S-EPMC3316495 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.

Schulze-Topphoff Ulf U   Shetty Aparna A   Varrin-Doyer Michel M   Molnarfi Nicolas N   Sagan Sharon A SA   Sobel Raymond A RA   Nelson Patricia A PA   Zamvil Scott S SS  

PloS one 20120330 3


Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting (RR) multiple sclerosis (MS). Using the animal model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), we examined how laquinimod promotes immune modulation. Oral laquinimod treatment reversed established RR-EAE and was associated with reduced central nervous system (CNS) inflammation, decreased Th1 and Th17 responses, and an increase in regulatory T cells (Treg). In  ...[more]

Similar Datasets

| S-EPMC6390632 | biostudies-literature
| S-EPMC6241855 | biostudies-literature
| S-EPMC7541690 | biostudies-literature
| S-EPMC2630467 | biostudies-literature
| S-EPMC3945470 | biostudies-literature
| S-EPMC4951702 | biostudies-other
| S-EPMC3532311 | biostudies-literature
| S-EPMC6667188 | biostudies-literature
| S-EPMC4704797 | biostudies-literature
| S-EPMC7197375 | biostudies-literature